Otonomy Inc.'s (Nasdaq: OTIC) Meniere's disease treatment Otividex failed a Phase 3 trial. Shares of the biopharmaceutical collapsed $17.22 to close at $3.58.
Otonomy's Otividex fails study
August 30, 2017 at 19:08 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.